• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Experimental EQ-HWB-9 Shows Construct Validity Across Three Gastrointestinal Cancers

by
November 21, 2026
in Health
Reading Time: 3 mins read
0
Experimental EQ-HWB-9 Shows Construct Validity Across Three Gastrointestinal Cancers

Experimental EQ-HWB-9 Shows Construct Validity Across Three Gastrointestinal Cancers

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A clinical study evaluating the psychometric properties of the experimental nine-item EQ Health and Wellbeing questionnaire, designated as the EQ-HWB-9 2022 version, has demonstrated generally satisfactory construct validity and preliminary evidence of responsiveness among patients diagnosed with gastric, pancreatic, and colorectal cancer.

The clinical investigation was conducted at a major tertiary hospital located in Shanghai, China, where researchers prospectively enrolled patients across three gastrointestinal oncology cohorts. The final analytical population comprised 502 total participants, specifically incorporating 164 patients with gastric cancer, 135 patients with pancreatic cancer, and 203 individuals undergoing treatment for colorectal cancer. Each participating patient completed the experimental EQ-HWB-9 along with established comparator instruments during two routine visits, while comprehensive clinical information was extracted directly from hospital medical records.

To evaluate convergent validity, the researchers examined how the experimental EQ-HWB-9 index score correlated with several widely recognized generic and cancer-specific instruments. Participants completed the generic EQ-5D-5L and SF-6Dv2 questionnaires during their visits. In addition, patients completed the FACT-G questionnaire, from which the preference-based FACT-8D utility score was extracted, and the EORTC QLQ-C30, from which the QLU-C10D index was derived, alongside single-item rating scales assessing global health status and overall quality of life.

The statistical analyses demonstrated moderate to strong positive correlations between the experimental EQ-HWB-9 index score and the comparative measures, with correlation coefficients ranging from 0.46 to 0.80 across the three cancer types. These substantial associations with the EQ-5D-5L, SF-6Dv2, FACT-8D, and QLU-C10D, as well as the global rating scales, confirmed convergent validity by demonstrating that the experimental nine-item tool effectively aligns with validated assessments of patient wellbeing and functional capacity.

Known-groups validity was also evaluated to determine how effectively the questionnaire distinguished between patient subsets characterized by differing physical and economic burdens. Across all three cancer types, the EQ-HWB-9 index score successfully differentiated patients according to their Eastern Cooperative Oncology Group performance status, generating large Cohen’s d effect sizes that ranged from 0.94 to 1.49. In addition, the measure demonstrated significant discriminative validity regarding patient-reported financial burden, producing Cohen’s d values between 0.38 and 0.49.

However, the instrument exhibited clear limitations when differentiating clinical disease stages. While known-groups validity for cancer stage was successfully demonstrated in both gastric and pancreatic cancer cohorts, displaying Cohen’s d effect sizes from 0.29 to 0.49, the experimental EQ-HWB-9 failed to discriminate cancer stage among patients with colorectal cancer.

Longitudinal responsiveness across routine clinical visits was analyzed through standardized response mean values, referred to as SRM metrics, calculated separately for anchor-defined improved and deteriorated patient groups. For patients categorized as improved, SRM values revealed noticeably higher responsiveness in pancreatic cancer than in gastric and colorectal cancer patients. Conversely, among anchor-defined deteriorated patients, SRM values were similar across all three cancers, showing that the questionnaire detected health deterioration with consistent sensitivity across the cohorts.

In their conclusions, the study authors affirmed that the experimental EQ-HWB-9 2022 version demonstrated generally satisfactory construct validity alongside preliminary responsiveness across these gastrointestinal malignancies.

Subject of Research: Psychometric evaluation of the experimental EQ-HWB-9 questionnaire in gastrointestinal cancer patients

Article Title: Construct validity and responsiveness of the EQ-HWB-9 in patients with gastric, pancreatic, and colorectal cancer

Article References: Zhang, X., Cheng, L. J., Zhou, T., Luo, N., & Ji, M. (2026). Construct validity and responsiveness of the EQ-HWB-9 in patients with gastric, pancreatic, and colorectal cancer. Health and Quality of Life Outcomes. https://doi.org/10.1186/s12955-026-02620-x

Image Credits: AI Generated

DOI: 10.1186/s12955-026-02620-x

Keywords: EQ-HWB-9, EQ-5D-5L, SF-6Dv2, FACT-8D, QLU-C10D, FACT-G, EORTC QLQ-C30, gastric cancer, pancreatic cancer, colorectal cancer, construct validity, known-groups validity, convergent validity, responsiveness, standardized response mean, ECOG performance status, financial burden, psychometric evaluation

News Source: Ophelia Keating. (November 21, 2026). Experimental EQ-HWB-9 Shows Construct Validity Across Three Gastrointestinal Cancers. Scienmag.

Tags: Colorectal cancerconstruct validityconvergent validityECOG performance statusEORTC QLQ-C30EQ-5D-5LEQ-HWB-9FACT-8DFACT-Gfinancial burdengastric cancerknown-groups validitypancreatic cancerpsychometric evaluationQLU-C10DresponsivenessSF-6Dv2standardized response mean
Share12Tweet7Share2ShareShareShare1

Related Posts

Fanconi Anemia Pathway Suppression of NHEJ Prevents MLL-Rearranged Leukemia Progression

Fanconi Anemia Pathway Suppression of NHEJ Prevents MLL-Rearranged Leukemia Progression

November 22, 2026
Mitral Annular Disjunction Requires Standard Valve Indications Rather Than Prophylactic Surgery

Mitral Annular Disjunction Requires Standard Valve Indications Rather Than Prophylactic Surgery

November 22, 2026

Blood and Gut Cell Analyses Match 140 Inflammatory Bowel Disease Risk Loci

November 22, 2026

Interleukin-11 Drives Amnion Cell Senescence and Triggers Preterm Labor in Mice

November 22, 2026

POPULAR NEWS

  • Mitral Annular Disjunction Requires Standard Valve Indications Rather Than Prophylactic Surgery

    Mitral Annular Disjunction Requires Standard Valve Indications Rather Than Prophylactic Surgery

    29 shares
    Share 12 Tweet 7
  • Blood and Gut Cell Analyses Match 140 Inflammatory Bowel Disease Risk Loci

    29 shares
    Share 12 Tweet 7
  • Interleukin-11 Drives Amnion Cell Senescence and Triggers Preterm Labor in Mice

    29 shares
    Share 12 Tweet 7
  • Study Details Chlamydia and Gonorrhea Co-Infection Rates in Hospital Patients

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Fanconi Anemia Pathway Suppression of NHEJ Prevents MLL-Rearranged Leukemia Progression

Improved Double-Buffer Extraction Yields High-Purity Genomic DNA from Rare Himalayan Tree

Mitral Annular Disjunction Requires Standard Valve Indications Rather Than Prophylactic Surgery

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.